We investigated the relationship of serum uric acid (UA) with resting forearm blood flow (FBF), reactive hyperaemia (RH) and flow-mediated dilation (FMD) of the brachial artery in hypertensive adults (n ¼ 506, mean age 62 years, 59% women). UA was measured by a colorimetric method. FBF, RH and FMD were measured by brachial artery ultrasound. Regression analyses were used to assess whether UA was associated with FBF, RH and FMD before and after adjustment for age, sex, systolic BP, diabetes, total and high-density lipoprotein cholesterol, smoking, body mass index (BMI), C-reactive protein (CRP), serum creatinine, alcohol intake, statin and diuretic use and brachial artery diameter (BAD). UA was significantly associated with FBF (Po0.0001) and RH (P ¼ 0.0001) but not with FMD (P ¼ 0.43). After adjustment for the covariates listed above, higher UA level remained independently associated with a higher FBF (P ¼ 0.012) and lower RH (P ¼ 0.004). The independent predictors were as follows: (a) higher FBF: lower age, higher BMI, history of smoking, statin use, higher CRP, higher BAD and higher UA levels; (b) lower RH: higher BMI, diabetes and higher UA levels; (c) lower FMD: greater age, male sex, higher BMI, history of smoking, statin use and higher BAD. We conclude that in hypertensive individuals, higher UA levels are associated with higher resting FBF and lower RH, markers of microvascular function, but not with brachial artery FMD.
Introduction
Uric acid (UA) is the end product of purine metabolism in humans, and serum levels are determined by dietary intake of purines, endogenous production from cellular turn over and renal function. In most mammals, the enzyme uricase converts UA into allantoin, resulting in low serum UA levels. In humans, however, the lack of uricase causes accumulation of uric acid. 1 UA has been implicated in target organ damage in hypertensive patients, 2 and it has been suggested that UA may play a role in early stages of cardiovascular damage in hypertension. 2 Whether UA is associated with measures of arterial function (such as endothelial function) in hypertensive individuals has not been clearly established. Endothelial dysfunction is characterized by decreased production and/or bioavailability of nitric oxide (NO), predisposing to vasoconstriction and thrombosis and playing a role in formation of atherosclerotic plaque. 3 Endothelial dysfunction precedes the clinical manifestations of atherosclerosis in subjects with cardiovascular risk factors. 4 It is well known that an impaired flow-mediated dilation is a marker of endothelial dysfunction. 3 Flow-mediated dilation of a conduit artery results when the artery is exposed to increased flow and shear stress and has been shown to be dependent on endothelium-derived NO. 3, 5 Brachial artery ultrasound and Doppler are used for non-invasive assessment of microvascular function. During this assessment, resting forearm blood flow (FBF) and reactive hyperaemia, markers of microvascular function, are also evaluated. 6 Increased resting blood flow and impaired reactive hyperaemia have been found to be associated with cardiovascular risk factors. [7] [8] [9] Reactive hyperaemia results predominantly from dilation of the microvasculature, and NO and other vasodilators likely contribute. 5 We investigated whether serum UA was associated with resting FBF, reactive hyperaemia and flowmediated dilation in a large sample of hypertensive patients.
Methods
The study population consisted of 506 hypertensive participants of the Functional Arterial Changes in Atherogenesis Study. The participants were recruited from the Genetic Epidemiology Network of Arteriopathy (GENOA) study, which included sibships with at least two members diagnosed with hypertension before the age of 60. Between January 2001 and December of 2005, 808 GENOA participants had completed brachial artery ultrasound. We excluded 204 normotensives, 82 with prior history of coronary artery disease or stroke, 15 with technically inadequate or missing brachial ultrasound images and one with an outlier total cholesterol value; the final sample for this study consisted of 506 hypertensive patients. This project was approved by the Mayo Institutional Review Board and participants gave informed consent.
Diabetes was considered present if a subject was being treated with insulin or oral agents or had a fasting glucose level X126 mg/dl. 'Ever' smoking was defined as having smoked more than 100 cigarettes in the past. The diagnosis of hypertension was established based on blood pressure (BP) levels measured at the study visit (systolic BP X140 mm Hg or BP X90 mm Hg) or the report of a prior diagnosis of hypertension and current treatment with medications for hypertension. Weight was measured by an electronic scale, height by a stadiometer and body mass index (BMI) was calculated in units of kg/m 2 . Information about the use of statins was obtained from a questionnaire administered to the participants. Alcohol consumption was quantified as ounces per week.
Blood was drawn by venipuncture after an overnight fast. Total cholesterol, high-density lipoprotein (HDL) cholesterol and fasting glucose were measured by standard enzymatic methods. Serum creatinine was measured by a spectrophotometric method and UA by a colorimetric method on a Hitachi 912 chemistry analyzer. The coefficient of variation of the UA assay was o7.5%. C-reactive protein (CRP) was measured by a highly sensitive immunoturbidimetric assay with a coefficient of variation o2.4%.
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Brachial artery ultrasound Participants were examined in the morning after an overnight fast and at least 12 h after taking any medications. Ultrasound assessment of brachial artery reactivity was performed in accordance with the guidelines of the International Brachial Artery Reactivity Task Force 6 using a 10 MHz linear array transducer (Acuson Sequoia, Mountain View, CA, USA), as previously described.
11 Flow-mediated dilation was calculated as the maximal percent increase in brachial artery diameter (BAD) from baseline during the first 90 s after the release of cuff occlusion. We calculated the increase in brachial blood flow as maximum flow recorded in the first 15 s after cuff deflation and expressed as a percent increase from baseline. We also assessed nitroglycerin-mediated dilation in 363 participants. We have previously shown reproducibility of this method. 12 Statistical methods Serum creatinine and CRP levels, as well as resting FBF, reactive hyperaemia, flow-mediated dilation and alcohol intake were log transformed to reduce excessive skewness. Univariable linear regression models were used to assess the association of UA with resting FBF, reactive hyperaemia, flowmediated dilation and nitroglycerin-mediated dilation. Multivariable linear regression models were employed to (a) determine independent predictors of resting FBF, reactive hyperaemia and flowmediated dilation and (b) investigate the association of UA with resting FBF, reactive hyperaemia, flowmediated dilation and nitroglycerin-mediated dilation, after adjustment for age, sex, coronary heart disease (CHD) risk factors (systolic blood pressure, diabetes, total cholesterol, HDL cholesterol, smoking and BMI), CRP, alcohol intake, statin and diuretic use. As baseline BAD influences basal flow, flowmediated dilation and reactive hyperaemia, we included BAD in the multivariable models. Backward elimination was then performed with a criteria of Po0.10 to enter and Po0.05 to stay in the model. Because serum creatinine is a known determinant of serum UA levels, it was included in the multiple regression models.
As our cohort consisted of sibships, we used population-averaged generalized estimating equations to account for the possible impact of familial correlations on the analyses. A P-value o0.05 was considered to be statistically significant. Statistical analyses were performed with SAS v 8.2 (SAS Institute, Cary, NC, USA).
Results
The mean age of participants was 62 years; 59% were women and 13.3% were diabetic (Table 1) . Mean (7s.d.) UA level was 6.2671.64 mg/dl. The remaining participant characteristics are presented in Table 1 .
Higher UA was significantly associated with higher resting FBF (Po0.0001) ( Figure 1 and Table 2) in univariate regression analysis. Other predictors of higher resting FBF in univariate analyses were greater age, male sex, higher BMI, diabetes, history of smoking, use of statins, higher total cholesterol, lower HDL cholesterol and higher serum creatinine (Table 2) . UA remained significantly associated with resting FBF after adjustment for age and sex (Po0.0001) and after further adjustment for CHD risk factors, CRP, serum creatinine, alcohol intake, statin and diuretic use (P ¼ 0.012). Other independent predictors of higher resting FBF were lower age, higher BMI, history of smoking, statin use, higher log CRP and higher BAD (Table 3) .
In univariate regression analysis, significant predictors of lower reactive hyperaemic flow were higher UA (Figure 1 , Po0.0001), greater age, higher BMI, diabetes, lower HDL cholesterol, greater log CRP and higher serum creatinine. (Table 2) . UA remained significantly associated with reactive hyperaemia after adjustment for age and sex (Po0.0001), and after further adjustment for CHD risk factors, CRP, serum creatinine, alcohol intake, statin and diuretic use (P ¼ 0.004). Other independent predictors of lower reactive hyperaemia were greater BMI and presence of diabetes (Table 3) .
UA was not significantly associated with flowmediated dilation in univariate analysis (P ¼ 0.43) ( Table 2 ). Significant univariable predictors of lower flow-mediated dilation were greater age, male sex, history of smoking and lower HDL cholesterol (Table 3 ). In multivariable regression analyses, independent predictors of lower flow-mediated dilation included greater age, male sex, BMI, history of smoking, use of statins and higher BAD (Table 3) . UA was not related to nitroglycerin-mediated dilation before (P ¼ 0.18) or after adjustment for age and sex (P ¼ 0.69) and further adjustment for CHD risk factors, CRP, serum creatinine, alcohol intake, statin and diuretic use (P ¼ non significant).
Discussion
In this study of hypertensive subjects without known CHD or stroke who underwent assessment of brachial artery vasoreactivity, we found that higher UA levels were independently associated with higher resting FBF and lower reactive hyperaemia but not with flow-mediated dilation of the brachial artery. To the best of our knowledge, this is the first report of an association of UA with resting and hyperaemic FBF, two measures of microvascular function, in a large community-based sample of hypertensive adults. 
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Previous studies have reported that cardiovascular risk factors such as hypercholesterolaemia, obesity, hypertension, smoking and male sex are associated with increased resting FBF. [7] [8] [9] 13 Cardiovascular risk factors and UA may induce a state of vasodilatation in the microcirculation, thereby increasing resting blood flow. Of note, Erdogan et al., 14 using transthoracic Doppler echocardiography to assess coronary flow reserve in 100 healthy volunteers, found that UA was associated with higher baseline coronary artery peak diastolic flow velocity.
Reactive hyperaemia following ischaemia is due to endothelial-independent vasodilators generated during ischaemia, 3, 5 as well as endothelial-derived NO. 15 Our findings of an inverse association between UA and hyperaemic FBF are consistent with prior studies. In the study by Erdogan et al., 14 UA was inversely associated with hyperaemic coronary artery diastolic flow velocity after dipyridamole infusion. In a study of 217 never-treated hypertensives, UA was inversely related to increase in FBF induced by intra-arterial infusion of acetylcholine, 16 and in 22 patients with chronic heart failure, UA was inversely related to reactive hyperaemia in lower limbs. 17 Previous studies that investigated the association of uric acid and flow-mediated dilation, a marker of endothelial function, yielded conflicting results. [18] [19] [20] Maxwell et al. 19 reported that UA was not independently associated with flow-mediated dilation in 458 subjects with CHD, a finding consistent with our results. On the other hand, an independent association between UA and flowmediated dilation was reported by Mercuro et al. 20 and Kato et al. 18 Whereas the participants from our study were all hypertensive and did not have known CAD or stroke, those reported by Mercuro were high risk subjects (10-year risk of CHD 420%), and those reported by Maxwell et al. 19 and Kato et al. 18 were younger and had few (or none) identifiable risk factors. Such differences may partially explain the lack of consistent 21, 20 UA has been shown to upregulate production of monocyte chemotactic protein-1 19 and CRP in vascular cells. 22 Indeed, we found higher higher UA to be independently associated with higher plasma CRP (P ¼ 0.002, analyses not shown). On the other hand, because it is a free-radical scavenger, 23 elevated UA levels may represent a reactive response to systemic inflammation. Furthermore, as production of UA is dependent on the activity of xanthine oxidase, which also produces oxygen free radicals in the setting of ischaemia, UA levels may also reflect the degree of vascular oxidative stress.
During periods of ischaemia, xanthine oxidase activity in the endothelial microvasculature leads to oxygen free radical and UA formation which in turn may impair post-ischemic hyperaemia. [24] [25] [26] This has motivated investigation of the effects of xanthine oxidase inhibitors on microvascular endothelial function. In animal models, allopurinol preserves microvascular endothelial function and blood flow in mesenteric vessels after resuscitation from haemorrhagic shock, 27 suggesting that xanthine oxidase may contribute to ischaemia reperfusion injury and associated endothelial dysfunction in this setting. Baldus et al. 28 demonstrated that oxypurinol improves coronary endothelial dysfunction in humans by markedly attenuating acetylcholine-induced vasoconstriction. More recently, high-dose allopurinol (600 mg) was shown to significantly improve forearm endothelial function, assessed by venous occlusion plethysmography, when compared to lower-dose allopurinol (300 mg) and placebo. 29 There is a considerable evidence suggesting that hyperuricaemia may be a causal factor in hypertension. [30] [31] [32] Several mechanisms for this relationship have been proposed, including an inter-relationship among UA, hyperinsulinemia, 30 pre-glomerular arteriolopathy and activation of the renin-angiotensin system, causing hypertension. 32 As hypertension is associated with microvascular disease, causing thickening of the microvascular walls and narrowing of the lumen, 33 it is possible that UA, hypertension and microvascular endothelial dysfunction are inter-related; however, further investigation is needed.
A strength of the present study is the inclusion of a large cohort of hypertensive individuals from the community. The main limitation of the study is its cross-sectional nature, and therefore, inferences about the directionality of the association between UA and resting FBF and reactive hyperaemia cannot be made. Our conclusions may also not be applicable to individuals of other ethnic groups.
To conclude, higher serum UA is independently associated with higher resting FBF and lower reactive hyperaemia, markers of microvascular function, in hypertensive individuals without history of CHD or stroke. These results raise the possibility that serum uric acid may play a role in the development of microvascular dysfunction in hypertensives. Prospective randomized trials are needed to study the effect of hypouricemic drugs on microvascular function and cardiovascular morbidity and mortality.
What is known about this topic K Increased serum uric acid level is a marker of increased cardiovascular risk. K Previous studies investigating the relationship between serum uric acid and arterial function have yielded conflicting results, with some showing a significant association, whereas others showing no such association.
What this study adds K The present study is the first to demonstrate an independent association between serum uric acid and microvascular function in a large sample of hypertensive subjects. K These results raise the possibility that serum uric acid may have a role in the development of microvascular dysfunction in hypertensives. Prospective randomized trials are needed to investigate the effect of hypouricemic drugs on microvascular function and cardiovascular morbidity and mortality.
